Waypoint Bio
New York City, United States
◆ Total Raised
$20M
◆ Stage
series-a
◆ Location
New York City, United States
◆ Founded
2021
◆ Team size
11-50
◆ Links
◆ About Waypoint Bio
AI-driven cell therapy startup developing in vivo CAR T therapeutics using spatial pooled screening and computer vision.
◆ What sets it apart
Its proprietary in vivo spatial pooled screening platform generates spatial, single-cell functional data from thousands of CAR T designs in parallel, enabling faster optimization than traditional serial testing.[2][3][4]
◆ Sectors
◆ Business
ModelSaaS
Customerbiopharma and drug development organizations developing advanced cell therapies, especially oncology-focused R&D teams
◆ Notable
- Raised $14.5M in seed funding in 2024
- Assembled a scientific advisory board of drug R&D and cancer experts
- Developing CAR T assets reported to show 15-fold greater potency and reduced on-target/off-tumor toxicity in animal models
◆ Backing funds on Raise
- Lux IXseries-a
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does Waypoint Bio do?
AI-driven cell therapy startup developing in vivo CAR T therapeutics using spatial pooled screening and computer vision.
Where is Waypoint Bio based?
Waypoint Bio is based in New York City, United States, founded in 2021.
How much has Waypoint Bio raised?
Waypoint Bio has raised $20M in tracked funding and is currently at the series-a stage.
Who has invested in Waypoint Bio?
Investors in Waypoint Bio include Hummingbird Ventures, Recode Ventures, Fifty Years, Builders VC, Dimension Capital, FPV Fund, Kinnevik and True Ventures.